Mary Couper
Impact in
- Toxicology top 0.5%
- Pharmacovigilance and Adverse Drug Reactions
-
- Antibiotic Use and Resistance
Papers in
-
- Pharmacovigilance and Adverse Drug Reactions 3
-
- Pharmaceutical Economics and Policy 2
- Housing Market and Economics 1
- Co-authors
- Sten Olsson (2 shared papers)Lolkje de Jong‐van den Berg (1 shared paper)Kees van Grootheest (1 shared paper)Andy Stergachis (1 shared paper)Shanthi Pal (1 shared paper)Robin J.M. Gray (1 shared paper)HV Hogerzeil (1 shared paper)Dinesh Kumar Mehta (1 shared paper)
- Journals
- Pharmacoepidemiology and Drug Safety (1 paper)Clinical Infectious Diseases (1 paper)Drug Safety (1 paper)The Lancet (1 paper)The Sociological Review (1 paper)
- Partner nations
- SwitzerlandSwedenGhana
In The Last Decade
Mary Couper
9 papers receiving 417 citations
Peers
Comparison fields: 5 of 96
- Toxicology 197
- Applied Microbiology and Biotechnology 33
- Geriatrics and Gerontology 51
- Economics and Econometrics 88
- Pediatrics, Perinatology and Child Health 55
Countries citing papers authored by Mary Couper
This map shows the geographic impact of Mary Couper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Couper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Couper more than expected).
Fields of papers citing papers by Mary Couper
This network shows the impact of papers produced by Mary Couper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Couper. The network helps show where Mary Couper may publish in the future.
Co-authors
The 12 scholars most cited alongside Mary Couper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 138 | |
| 2 | 2010 | 128 | |
| 3 | 1997 | 52 | |
| 4 | 1997 | 41 | |
| 5 | 2002 | 32 | |
| 6 | 2007 | 26 | |
| 7 | 2008 | 17 | |
| 8 | 1975 | 16 | |
| 9 | WHO model formulary | 2002 | 1 |
About Mary Couper
Mary Couper is a scholar working on Toxicology, Economics and Econometrics, Public Health, Environmental and Occupational Health, Infectious Diseases and Pediatrics, Perinatology and Child Health, having authored 9 papers that have together received 451 indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (3 papers), Pharmaceutical Economics and Policy (2 papers), Academic integrity and plagiarism (1 paper), Antibiotic Use and Resistance (1 paper), Opioid Use Disorder Treatment (1 paper), Tuberculosis Research and Epidemiology (1 paper), Pharmacological Effects and Toxicity Studies (1 paper) and Housing Market and Economics (1 paper). The work is most often cited by research in Toxicology (197 citations), Applied Microbiology and Biotechnology (33 citations), Geriatrics and Gerontology (51 citations), Economics and Econometrics (88 citations) and Pediatrics, Perinatology and Child Health (55 citations). Mary Couper has collaborated with scholars based in Switzerland, Sweden and Ghana. Frequent co-authors include Sten Olsson, Lolkje de Jong‐van den Berg, Kees van Grootheest, Andy Stergachis, Shanthi Pal, Robin J.M. Gray, HV Hogerzeil, Dinesh Kumar Mehta, Ralph Edwards and Sam Adjei. Their work appears in journals such as Pharmacoepidemiology and Drug Safety, Clinical Infectious Diseases, Drug Safety, The Lancet and The Sociological Review.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.